Cy­to­ki­net­ics cheers a PhI­II read­out for their heart drug de­vel­oped with Am­gen, but an­a­lysts and in­vestors aren't join­ing the par­ty

Fif­teen years af­ter it en­tered the clin­ic, Am­gen $AMGN and Cy­to­ki­net­ics’ close­ly watched heart drug popped out the oth­er side, meet­ing the pri­ma­ry end­point in a Phase III study. But it missed key sec­ondary end­points in­clud­ing re­duc­tion in car­dio­vas­cu­lar death — and Cy­to­ki­net­ics CEO Robert Blum said whether they’ll ap­proach reg­u­la­tors is still up for dis­cus­sion.

“It seems rea­son­able to as­sume that that will oc­cur. But we’ve not made any de­ci­sions on that,” Blum told End­points News. While the com­pa­nies cel­e­brat­ed the re­sults at this year’s AHA, Cy­to­ki­net­ics’ stock $CYTK slipped just over 5% be­fore the bell.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.